Treatments for severe psoriasis: update
- John R Sullivan, Veronica A Preda
- Aust Prescr 2009;32:50
- 1 April 2009
- DOI: 10.18773/austprescr.2009.024
In March 2009 it was announced that efalizumab would be withdrawn from the Australian market. This follows a review of the drug in Europe which found the benefits no longer outweigh the risk of harm. There are reports of progressive multifocal leucoencephalopathy arising in patients who have been treated with efalizumab for more than three years.1 The drug has also been under review in the USA.2
Comment from Dr JR Sullivan and Dr V Preda, the authors of an article about treating severe psoriasis recently published in Australian Prescriber (Aust Prescr 2009;32:14-18):
For rare side effects it takes a number of years of post-marketing surveillance for a signal to appear. This can take longer for therapies with only a single therapeutic indication such as efalizumab. This drug has only been used in 46 000 patients worldwide.
The tumour necrosis factor-alfa antagonists, infliximab and etanercept, for psoriasis have been used for a number of clinical indications over a much longer period. We have 15 years of patient safety data and over 1.4 million patient years and 630 000 patients with etanercept, and 15 years of patient safety data and 4.3 million patient years and 340 000 patients with infliximab. For these two drugs much more is known about their longer-term safety profiles.
The use of biologicals for the treatment of severe psoriasis needs to be considered in light of the safety profile of each drug and also in the context of the individual patient. Biologicals are not only used in severe psoriasis but also for a number of other disorders. Thus with regard to safety data we can benefit from the experience with these medications used in other specialties such as rheumatology and gastroenterology. From rheumatology we know to screen for tuberculosis before starting therapy to help prevent potentially serious infections. Although adverse effects are often grouped together as a class effect, it is important to consider each biological drug individually as they have their own unique pharmacological profiles.
Dermatologist and Clinical Pharmacologist, Southderm Kogarah, Skin and Cancer Foundation Australia, St Vincent's Hospital, and University of New South Wales
Dermatology Research Officer, Skin and Cancer Foundation Australia, St Vincent's Hospital and University of New South Wales, Sydney